Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.
Takeshi HatanakaSatoru KakizakiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraNoritomo ShimadaKazuhito KawataHisashi KosakaTakaaki TanakaHideko OhamaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiAtsushi NaganumaYohei KoizumiShinichiro NakamuraKouji JokoMasaki KaiboriHiroko IijimaYoichi HiasaTakashi Kumadanull nullPublished in: Cancer medicine (2022)
Our etiology-based study demonstrated that Atez/Bev showed good efficacy and safety for HCC patient with non-viral infection as well as those with viral infection.